Compare SUPX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUPX | AGIO |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2024 | 2013 |
| Metric | SUPX | AGIO |
|---|---|---|
| Price | $12.72 | $28.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $36.25 |
| AVG Volume (30 Days) | 277.0K | ★ 1.4M |
| Earning Date | 10-24-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,596,575.00 | ★ $44,791,000.00 |
| Revenue This Year | N/A | $27.83 |
| Revenue Next Year | N/A | $134.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.88 | ★ 36.26 |
| 52 Week Low | $3.55 | $22.24 |
| 52 Week High | $76.50 | $46.00 |
| Indicator | SUPX | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 31.56 | 52.45 |
| Support Level | $13.43 | $26.25 |
| Resistance Level | $14.99 | $28.87 |
| Average True Range (ATR) | 1.04 | 1.05 |
| MACD | 0.57 | 0.21 |
| Stochastic Oscillator | 14.25 | 71.94 |
Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.